ArticleNeuropsychiatric disease and treatment2019
Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm.
Article in Neuropsychiatric disease and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: a systematic review and meta-analysis.BMC neurology · 2024Pooled it
- Psychological and motor outcomes of botulinum toxin in hemifacial spasm and blepharospasm.International ophthalmology · 2026Article
- Sustained anxiolytic and antidepressant effects of botulinum toxin A in blepharospasm patients beyond motor symptom control.World journal of psychiatry · 2026Article
- Beyond aesthetic outcomes: psychodermatological benefits of botulinum toxin treatment in the upper facial third. A narrative review.Frontiers in psychiatry · 2026Review
- Botulinum Toxin: An Unconventional Tool for the Treatment of Depression?Brain sciences · 2025Review
- Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.Brain and behavior · 2025Article
- Hemifacial Spasm and Blepharospasm: Divergent Social Cognition Performance Despite Similar Neurocognitive Profiles.Brain and behavior · 2025Article
- The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation.Journal of cosmetic dermatology · 2025Review
- Intradermally injected abobotulinumtoxinA administered preemptively before surgery alleviates post-surgical pain and normalizes behavior in a translational animal model.Scientific reports · 2025Article
- Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin.Acta neurologica Belgica · 2025Article
- Minimal important changes of HFS-30 and HFS-7 questionnaires for patients with hemifacial spasm.Clinical parkinsonism & related disorders · 2025Article
- Does botulinum toxin affect psycho-social aspects in dystonia?Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Review
- Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome.Frontiers in neurology · 2023Article
- Botulinum Toxin in Facial Aesthetics Affects the Emotion Process: A Meta-analysis of Randomized Controlled Trials.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Review
- THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.Acta clinica Croatica · 2022Article
- Treatment of Depression with Botulinum Toxin.Toxins · 2022Review
- Serum Metabolomics of Benign Essential Blepharospasm Using Liquid Chromatography and Orbitrap Mass Spectrometry.Oxidative medicine and cellular longevity · 2022Article
- Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the efficacy of botulinum toxin type A (BTX-A) therapy in relieving anxiety and depression in patients with hemifacial spasm (HFS) and benign essential blepharospasm (BEB). PATIENTS AND
methodNinety idiopathic HFS patients and 90 BEB patients were enrolled. The anxiety and depression status were evaluated by self-rating anxiety scale (SAS) and self-rating depression scale (SDS), respectively, before and after the injection of BTX-A.
resultsBefore treatment, the SAS and SDS scores of HFS patients were 41.25±6.35 and 42.25±7.57, respectively. The SAS scores were 40.17±8.36 for males and 43.56±6.10 for females (
conclusionIn HFS and BEB, especially in female patients, there is an association with anxiety and depression. BTX-A can improve the symptoms of anxiety and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.